The Medicines and Healthcare products Regulatory Agency confirmed on 10 August that it had authorised orforglipron, sold under the brand name Foundayo, making Britain the first country in Europe to licence an oral GLP-1 receptor agonist for both weight management and type 2 diabetes. Julian Beach, the MHRA’s executive director of healthcare quality and access, described the decision as following rigorous assessment of the drug’s safety, quality and effectiveness, and said the regulator would keep it under close review as a prescription-only medicine.
The licence covers adults with a body mass index of 30 or above, or between 27 and 30 with at least one weight-related comorbidity, when combined with a reduced-calorie diet and increased activity. It also extends to improving glycaemic control in patients whose type 2 diabetes is not adequately managed by existing treatment. Unlike injectable GLP-1 drugs such as semaglutide, orforglipron is a small-molecule tablet that does not require fasting or the food and water restrictions attached to oral semaglutide, a distinction Lilly and the regulator have both pointed to as a meaningful adherence advantage for patients who are reluctant to self-inject or find the dietary timing of existing oral options impractical.
A meaningful share of NHS patients eligible for GLP-1 therapy either decline injectable treatment outright or struggle with the logistics of it, particularly older patients, those with needle phobia, and people managing multiple long-term conditions who already juggle several medication routines. An oral option with fewer restrictions widens the pool of patients for whom GLP-1 therapy becomes a realistic proposition, which is precisely why the authorisation has been welcomed by pharmacy bodies as significant for a population that current injectable options do not reach.
None of which means Foundayo is available through the NHS. The MHRA licence governs whether a medicine may be sold in the UK; it says nothing about whether the NHS will pay for it. That decision sits with the National Institute for Health and Care Excellence, which has yet to complete a cost-effectiveness evaluation, and until it does, prescribing under NHS Elective care remains theoretical. This is not a formality. NICE has previously declined to recommend medicines that MHRA has licensed, citing value for money, and the interval between authorisation and a funding decision has historically stretched well beyond ninety days.
The government has tried to close that interval through the Aligned Pathway, a joint MHRA-NICE initiative launched to let licensing and cost-effectiveness assessments run concurrently rather than consecutively, with the explicit aim of cutting the delay by three to six months. Foundayo’s authorisation is an early test of whether that mechanism delivers in practice rather than in principle, and the answer will matter well beyond this one drug. GLP-1 therapies are proliferating fast, with multiple branded products now holding or pursuing UK and EU authorisation, and NICE’s capacity to keep pace with that volume without becoming a bottleneck is now a live question for a technology assessment system built for a slower era of drug development.
There is a wider political dimension too. Ministers have made faster access to innovative medicines a stated marker of the life sciences and NHS productivity agenda, and a licensing win that stalls for months at the appraisal stage undercuts that argument publicly. For NHS leaders and primary care, the practical planning question is less about Foundayo’s mechanism of action and more about prescribing capacity and formulary readiness should NICE recommend it, given how quickly demand for weight-loss and diabetes medication has already outstripped supply chains once before. The MHRA has done its part quickly. Whether the rest of the system can match that pace is the story that follows.
